Spike Protein News and Research

RSS

The "Great Escape" by SARS-CoV-2 XBB.1

In a recent article published in the Lancet Microbe, researchers in the Netherlands and the United Kingdom quantified the antigenic diversity of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants, BQ.1.1, BM.1.1.1, and XBB.1, all derivatives of the variant of concern (VOC) Omicron, which emerged in late 2022.

17 Jan 2023

Future COVID-19 control will require vaccines that induce better mucosal immunity

In a recent study posted to the medRxiv* preprint server, researchers in France explored the relationship between long-term immunoglobulin (Ig)-A response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and taste and smell disorders.

17 Jan 2023

On four flights out of China in December, 22% of passengers were SARS-CoV-2 positive

Researchers document COVID-19 screening results in Italy of 556 flight passengers from two Chinese provinces in late December 2022.

17 Jan 2023

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

Researchers from the United States evaluated the efficacy and immunogenicity of an intranasal messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine against SARS-CoV-2 using a hamster model.

16 Jan 2023

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

Researchers assessed the effectiveness of a multivalent exosome-based coronavirus disease 2019 (COVID-19) vaccine.

16 Jan 2023

CNB-CSIC vaccine fully protects against SARS-CoV-2 infection of the brain

In a recent study published in the journal Nature Neuroscience, researchers in Spain described the effectiveness of a modified vaccinia virus Ankara (MVA) vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate in protecting against SARS-CoV-2 infection in the brain using a mouse model.

12 Jan 2023

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

Scientists have recently conducted a cell-based high-content screening of over 300 natural compounds and identified three compounds with potent antiviral activities against SARS-CoV-2 and its variants.

12 Jan 2023

Using lipid nanoparticles and messenger RNA to treat blindness associated with rare genetic condition

Oregon State University College of Pharmacy scientists have demonstrated in animal models the possibility of using lipid nanoparticles and messenger RNA, the technology underpinning COVID-19 vaccines, to treat blindness associated with a rare genetic condition.

11 Jan 2023

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

Researchers discovered that the spike protein of SARS-CoV-2 is susceptible to cleavage at the disulfide bonds, and the vulnerability to reductive cleavage varies across variants, with the Omicron variant family being highly susceptible to reduction.

10 Jan 2023

Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfections

Researchers used electronic health records to characterize the incidence, biomarkers, attributes, and severity of SARS-CoV-2 reinfections and evaluated the association between reinfections and long coronavirus disease (COVID).

10 Jan 2023

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

In a recent correspondence published in The Lancet Infectious Diseases journal, researchers in Germany assessed the neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB.1 lineage.

9 Jan 2023

Deletions in the antigenic regions in SARS-CoV-2 increase transmission and immune evasion ability

A recent study published in the journal Scientific Reports examined the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole genome data to determine the deletion mutations around the spike protein region associated with increased transmission of the virus and identified an increase in the deletion-prone spike protein regions indicating an evolution strategy for immune escape.

9 Jan 2023

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

8 Jan 2023

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

5 Jan 2023

Bacterial outer membrane vesicles: utility as vaccines and novel engineering approaches

Scientists have described the utility of gram-negative bacteria-derived outer membrane vesicles as vaccines and methods to expand their applications.

3 Jan 2023

Effects of hybrid immunity on humoral immune response following COVID mRNA vaccination in a cohort of essential and frontline workers

Researchers longitudinally evaluated humoral immune responses to the second and third doses of COVID-19 mRNA vaccines among individuals with and without prior history of SARS-CoV-2 infections.

3 Jan 2023

What is the impact of COVID-19 on the human genetic architecture?

Researchers recently described the second update on the study of human genetic architecture with respect to the effect of coronavirus disease 2019 (COVID-19).

3 Jan 2023

BA.4/BA.5 mutations reduced responsiveness of epitope-specific T cells with original mRNA vaccine

A new study in the journal Viruses examines the phenomenon of breakthrough infections due to the evasion of T-cell immunity by the Omicron BA.4/BA.5 subvariants, showing this to be due to spike gene mutations.

2 Jan 2023

Hybrid immunity from mRNA vaccines and breakthrough Omicron infections induces stronger immune responses against Omicron BQ.1.1

Researchers evaluated plasma samples from individuals vaccinated with a fourth booster dose of mono- or bivalent mRNA SARS-CoV-2 vaccine to evaluate the recognition and neutralization capacity against the ancestral (D614G) strain and the Omicron BQ.1.1 subvariant.

23 Dec 2022

COVID-19 vaccination protects people with B cell lymphoma and multiple myeloma

A recent Nature Cancer study documented that individuals with B cell lymphomas (LY) and multiple myeloma (MM) developed potent infection neutralization capabilities against several SARS-CoV-2 variants of concern (VoCs).

22 Dec 2022

Spike Protein News and Research

The "Great Escape" by SARS-CoV-2 XBB.1

Future COVID-19 control will require vaccines that induce better mucosal immunity

On four flights out of China in December, 22% of passengers were SARS-CoV-2 positive

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

CNB-CSIC vaccine fully protects against SARS-CoV-2 infection of the brain

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

Using lipid nanoparticles and messenger RNA to treat blindness associated with rare genetic condition

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfections

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

Deletions in the antigenic regions in SARS-CoV-2 increase transmission and immune evasion ability

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

Bacterial outer membrane vesicles: utility as vaccines and novel engineering approaches

Effects of hybrid immunity on humoral immune response following COVID mRNA vaccination in a cohort of essential and frontline workers

What is the impact of COVID-19 on the human genetic architecture?

BA.4/BA.5 mutations reduced responsiveness of epitope-specific T cells with original mRNA vaccine

Hybrid immunity from mRNA vaccines and breakthrough Omicron infections induces stronger immune responses against Omicron BQ.1.1

COVID-19 vaccination protects people with B cell lymphoma and multiple myeloma

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News